D. Boral Capital Reiterates “Hold” Rating for FibroBiologics (NASDAQ:FBLG)

FibroBiologics (NASDAQ:FBLG)‘s stock had its “hold” rating restated by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday, MarketBeat.com reports.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright lowered their target price on shares of FibroBiologics to $4.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, FibroBiologics presently has an average rating of “Hold” and an average price target of $5.50.

FibroBiologics Stock Performance

NASDAQ:FBLG opened at $0.20 on Thursday. FibroBiologics has a 52-week low of $0.19 and a 52-week high of $1.53. The stock has a fifty day moving average of $0.30 and a 200 day moving average of $0.35. The firm has a market capitalization of $13.81 million, a price-to-earnings ratio of -0.47 and a beta of -0.69.

FibroBiologics shares are going to reverse split on the morning of Monday, March 30th. The 1-20 reverse split was announced on Wednesday, March 25th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, March 27th.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.06. Equities analysts forecast that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Jason Davis acquired 70,000 shares of FibroBiologics stock in a transaction dated Monday, March 2nd. The shares were purchased at an average cost of $0.41 per share, for a total transaction of $28,700.00. Following the transaction, the chief financial officer owned 70,000 shares of the company’s stock, valued at $28,700. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders bought 191,500 shares of company stock valued at $72,893. 13.00% of the stock is currently owned by corporate insiders.

Institutional Trading of FibroBiologics

Hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC bought a new position in FibroBiologics during the first quarter valued at approximately $29,000. XTX Topco Ltd raised its stake in shares of FibroBiologics by 160.0% during the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after acquiring an additional 28,276 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of FibroBiologics in the 2nd quarter valued at $49,000. Cerity Partners LLC boosted its stake in shares of FibroBiologics by 37.2% in the 2nd quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after purchasing an additional 34,702 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of FibroBiologics during the 2nd quarter valued at $60,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.